Tech Company Financing Transactions
Ampersand Biomedicines Funding Round
On 3/7/2023, Ampersand Biomedicines landed $50 million in funding from Flagship Pioneering.
Transaction Overview
Company Name
Announced On
3/7/2023
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Undisclosed
Investors
Flagship Pioneering (Lead Investor)
Proceeds Purpose
The newly launched company aims to design programmable, tissue-selective medicines.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
135 William T. Morrissey Blvd
Boston, MA 02125
USA
Boston, MA 02125
USA
Phone
Undisclosed
Website
Email Address
Overview
Developer of medicines and body therapeutics designed to act at the site of disease. The company combines a localizing element that enables disease-specific precision with an actuator specifically chosen for disease modification, enabling researchers to navigate a large range of diseases in almost all areas of the body.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Noubar Afeyan
Chief Executive Officer
Avak Kahvejian
Chief Technical Officer
Daniel Blom
Browse more venture capital transactions:
Prev: 3/7/2023: Kresus venture capital transaction
Next: 3/7/2023: Evove venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs